you are here:

Amgen

SYMBOL:AMGN|SECTOR:Health Care|DERIVED:CFD

1.75 (0.55%)

As on 11 Dec, 2025 | 23:17 IST

Day Range

312.53

320.19

52 Week Range

253.95

346.38

Advance Chart

Overview
Chart
MC Technicals
Returns
Financials
Peers
News
About the Company

Open	315.49
Previous Close	315.38
Beta	0.01

High	320.19
Low	312.53
TTM EPS See historical trend	21.87(+13.79% YoY)

52 Week High	346.38
52 Week Low	253.95
TTM PE See historical trend	14.50(Low PE)

Mkt. Cap ($ Billion)	170.47
Dividend Yield	3.33

Advanced Chart

*Delayed by 20 seconds

MC Technicals

Technical rating

This represents current trend.
Click here for disclaimer.

Trend

Bearish

See Details

Historical Rating

Moving Averages	Neutral
Technical Indicators	Bearish
Moving Averages Crossovers	Neutral

Pivot levels

Type	R1	R2	R3	PP	S1	S2	S3
Classic	317.48	319.57	321.76	315.29	313.19	311.00	308.91
Fibonacci	316.93	317.94	319.57	315.29	313.65	312.64	311.00
Camarilla	315.77	316.17	316.56	315.29	314.99	314.59	314.20

Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.

Moving Averages

Days
5	319.6
10	330.5
20	334.98
50	314.87
100	301.68
200	297.71

Returns

Price Performance

1 Week		-6.77%
1 Month		-6.30%
3 Months	12.18%
YTD	21.70%
1 Year	16.10%
3 Years	13.81%

Financialsin million $

Peers

Name	Price ($)	Change%	M.Cap(Billion $)	TTM PE	TTM EPS	DY	52 wk high/low		Technical Rating
Eli Lilly	1,018.86	2.54	968.70	46.33	21.99	0.74	1,111.99/623.99	2.81	Bullish
J&J	209.88	1.62	505.77	20.22	10.38	2.83	211.23/141.30	8.97	Very Bullish
AbbVie	222.85	-1.03	393.81	23.58	9.45	3.49	244.80/164.59	-1.05	Bearish
Merck	98.77	1.18	250.15	11.42	8.65	3.86	105.77/73.35	9.05	Bullish
Amgen	317.13	0.55	170.47	14.50	21.87	3.33	346.38/253.95	-6.30	Bearish

+ See More

Market news

Wall Street closes with slight gains as data keeps Fed cut expectations on track

December 6, 2025 8:34 AM

About the company

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.